The use of internal urethrotomy for treatment of urethral stricture remains a controversial topic in urology.
To investigate outcomes and predictors of failure for internal urethrotomy as primary treatment for untreated bulbar urethral strictures.
We performed a retrospective analysis of patients who underwent internal urethrotomy. Patients with bulbar urethral stricture who did not receive any previous treatment were included. Patients with traumatic, penile or posterior urethral strictures, lichen sclerosus, failed hypospadias repair, or stricture length >4cm were excluded.
The primary outcome was treatment failure. Kaplan-Meyer plots were used to depict treatment failure-free survival. Univariate and multivariable Cox regression analyses were used to test the association between predictors (age, body mass index, diabetes, history of smoking, etiology, stenosis type and length, preoperative maximum flow [pQmax]) and treatment failure.
Overall, 136 patients were included. The median stricture length was 2cm. Median follow-up was 55 mo. At 5-yr follow-up the failure-free survival rate was 57%. On univariate analysis, diabetes, nonidiopathic etiology, stricture length of 3-4cm, and pQmax were significantly associated with treatment failure. These predictors were included in a multivariable analysis, in which pQmax was the only significant predictor of treatment failure.
Failure of internal urethrotomy for untreated bulbar urethral strictures greatly depends on pQmax flow at uroflowmetry. Patients with pQmax >8ml/s have a high probability of success, while patients with pQmax <5ml/s have a low probability of success.
The use of internal urethrotomy in patients with an untreated bulbar urethral stricture should only be considered in selected cases.
European urology focus. 2018 Nov 05 [Epub ahead of print]
Guido Barbagli, Nicola Fossati, Francesco Montorsi, Sofia Balò, Claudio Rimondi, Alessandro Larcher, Salvatore Sansalone, Denis Butnaru, Massimo Lazzeri
Centro Chirurgico Toscano, Arezzo, Italy., Department of Urology, Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Department of Experimental Medicine and Surgery, University Tor Vergata, Rome, Italy., Institute for Regenerative Medicine, Sechenov First Moscow State Medical University, Moscow, Russia., Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Milan, Italy. Electronic address: .